Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 El.U.). A controlled study in adults

Vaccine

Volumn 14, Issue 11, 1996, Pages 1028-1030

  Gil, Angel ^a   González, Antonio ^b   Dal Ré, Rafael ^b   Calero, Juan Rey ^a  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Interference; Single dose Hepatitis A vaccine; Yellow Fever vaccine

Indexed keywords

HEPATITIS A VACCINE; YELLOW FEVER VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS A; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION; YELLOW FEVER;

EID: 0030219789     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(96)00059-X     Document Type: Article

References (13)

1. 1 Centers for Disease Control. Health Information for International Travel. US Dept of Health and Human Services, Atlanta, GA, 1992, pp. 81-129
2. 2 Van Damme, P., Mathei, C., Thoelen, S., Meheus, A., Safary, A. and André, F.E. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J. Med. Virol. 1994, 44, 435-441
3. 3 Victor, J., Knudsen, J.D. and Nielsen, L. Hepatitis A vaccine. A new convinient single-dose schedule with booster dose when long-term immunization is warranted. Vaccine 1994, 12, 1327-1329
4. 4 Freestone, D.S. Yellow Fever vaccine. In: Vaccines, 2nd edn (Eds Plotkin, S.A. and Mortimer, E.A.). WB Saunders Company, London, 1994, pp. 741-779
5. 5 Hinman, A.R., Orestein, W.A., Bart, K.J. and Preblud, S.R. Immunization. In: Principles and Practice of Infectious Diseases, 3rd edn (Eds Mandell, G.L., Douglas, R.G. and Bennett, J.E.). Churchill Livingston, New York, 1990, pp. 2320-2333
6. 6 Briem, H., Wynen, J. and Safary, A. Immunogenicity and reactogenicity of a hepatitis A virus (HAV) vaccine administered as a single dose with a booster at 6 months. International Symposium on Viral Hepatitis and Liver Disease, 10-14 May 1993; Tokyo, Japan. Abstract 048
7. 7 Pocock, S.J. The size of a clinical trial. In: Clinical Trials. A Practical Approach, 1st edn. John Wiley and Sons, Chichester, 1993, pp. 123-138
8. 8 Van Damme, P., Thoelen, S., Gramm, M., De Groote, K., Safary, A. and Meheus, A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity and long-term antibody persistence. J. Med. Virol. 1994, 44, 446-451
9. 9 Gil, A., González, A., Dal-Ré, R., Aguilar, L., Malo, C. and Rey, J. Evaluación de la inmunogenicidad y seguridad en adultos sanos de una vacuna antihepatitis A inactivada. Med. Clin. (Barc.) 1994, 102, 769-771
10. 10 André, F., D'Hondt, E., Delem, A. and Safary, A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992, 10Suppl. 1, S160-S168
11. 11 Receveur, M.C., Quiniou, J.M., Delprat, P., Monlun, E., Lehner, V. and Le Bras, M. Vaccination simultanée contre l'hépatite A et la fiévre jaune. Bull. Soc. Path. Exot. 1993, 86, 406-409
12. 12 Kruppenbacher, J., Bienzle, U., Bock, H.L. and Clemens, R. Co-administration of an inactivated hepatitis A vaccine with other travellers vaccines: interference with the immune response. 34th International Conference of Antimicrobial Agents and Chemotherapy, 4-7 October 1994; Orlando, USA. Abstract: H115
13. 13 Van Dooslaer, E., Tormans, G. and Van Damme, P. Cost-effectiveness analysis of vaccination against hepatitis A in travellers. J. Med. Virol. 1994, 44, 463-469